CHICAGO -- An oral investigational agent effectively shrank tenosynovial giant cell tumors (TGCTs) while demonstrating functional and symptomatic benefits for patients, the phase III MOTION trial ...

US FDA grants full approval of Deciphera’s Romvimza™ (vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT). News release. Deciphera Pharmaceuticals. February 14 ...

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer. Safety results from ...

Treatment with emactuzumab has received fast track designation from the United States Food and Drug Administration (FDA) for patients with tenosynovial giant cell tumor (TGCT) who are not amenable to ...

Cassier PA, Italiano A, Gomez-Roca C, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

About Tenosynovial Giant Cell Tumor (TGCT) TGCT is a rare disease caused by a translocation in colony-stimulating factor 1 (CSF1) ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of ...

Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old.